University of Cambridge
The University of Cambridge, founded in 1209, is a prestigious public research university located in Cambridge, United Kingdom. It is organized into 31 colleges and 150 departments, encompassing six schools: Arts and Humanities, Biological Sciences, Clinical Medicine, Humanities and Social Sciences, Physical Sciences, and Technology. With a diverse community of over 20,000 students and 12,000 staff members from around the globe, the university offers a wide range of undergraduate, graduate, and postgraduate programs across various disciplines, including humanities, sciences, law, and engineering. In addition to its educational offerings, the university is renowned for its extensive research activities, which span fields such as clinical medicine, biomedicine, and engineering. The institution also manages museums, libraries, and collections, and actively commercializes intellectual properties developed within its academic framework. The University of Cambridge is recognized as one of the world's leading academic institutions, noted for its historical significance, outstanding academic achievements, and contributions to research and knowledge.
Top Stages
113 past transactions
Robin AI
Series B in 2024
Robin AI is a legal technology startup focused on automating legal processes through artificial intelligence. Its software enhances the contract mark-up process by providing essential features while ensuring enterprise-grade encryption and security, which helps safeguard sensitive data. The platform empowers legal teams to delegate low-complexity tasks, thereby simplifying and streamlining legal workflows. By automating routine aspects of legal work, Robin AI enables professionals to concentrate on more complex and high-value tasks, ultimately improving productivity and efficiency within legal practices.
Xwatts
Pre Seed Round in 2024
Xwatts is a developer of an intelligent energy management system specifically designed for commercial buildings. The company focuses on reducing costs and emissions through continuous analysis of energy usage patterns, environmental conditions, and market data. By optimizing and automating electricity consumption, Xwatts enables building owners to take direct control of their distributed energy assets. The system evaluates historical usage alongside real-time market data to enhance asset scheduling and minimize electricity consumption costs, thereby promoting more efficient energy management in commercial properties.
Wave Photonics
Seed Round in 2024
Wave Photonics is a company based in Cambridge, UK, focused on enhancing the design and integration of integrated photonics products. It develops a platform that utilizes computational techniques to optimize product designs and streamline the supply chain. This platform offers a software tool that predicts the performance and variability of components based on specific fabrication processes, along with an optimizer to create a library of foundry-specific components. By facilitating the development and mass production of integrated photonics technologies, Wave Photonics aims to improve efficiency and reduce redundancy for businesses in the sector.
Echion Technologies
Series B in 2024
Echion Technologies, founded in 2017 and based in Cambridge, United Kingdom, specializes in developing advanced anode materials for lithium-ion (Li-ion) batteries. Their proprietary XNO® material offers faster charging times, longer lifespans, and improved safety compared to traditional options. The company targets the heavy-duty electric vehicle market, aiming to enhance efficiency and sustainability within the transportation sector by providing optimized power anode materials for cost-effective battery production.
Zetta Genomics
Seed Round in 2024
Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.
Xampla
Series B in 2024
Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, focused on developing and producing plant protein-based materials as sustainable alternatives to conventional plastics. Founded in 2018, Xampla specializes in creating biodegradable and biocompatible products, including microcapsules, beads, films, threads, and various other structures made entirely from pea protein. These materials are designed for diverse commercial applications, spanning sectors such as food, cosmetics, household products, animal feed, packaging, and medical uses. By eliminating synthetic ingredients and reducing reliance on polluting plastics, Xampla aims to provide environmentally friendly solutions that align with the growing demand for sustainable materials in the marketplace.
T-Therapeutics
Series A in 2023
T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.
Nu Quantum
Seed Round in 2023
Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.
Materials Nexus
Seed Round in 2023
Materials Nexus is a deep-tech company specializing in accelerating sustainable materials innovation. It automates complex quantum calculations at scale, enhancing accuracy and efficiency. The company's core business lies in developing a material modeling platform that integrates quantum mechanics and artificial intelligence. This platform facilitates the creation of greener, more sustainable materials with reduced greenhouse gas emissions, primarily targeting the construction sector for access to eco-friendly building materials.
RoboK
Seed Round in 2023
RoboK Limited is a computer vision startup based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing simultaneous localization and mapping (SLAM) algorithms and innovative 3D sensing technologies for various applications, particularly in the automotive and industrial sectors. RoboK aims to enhance safety and performance in industrial workplaces by maximizing the value of existing CCTV systems. Its platform provides a modular and scalable solution for object detection, classification, tracking, and depth estimation, enabling clients to transform passive visual data into actionable insights. The company collaborates with major critical infrastructure operators to optimize their operations through advanced visual analytics.
Planetary Processing
Pre Seed Round in 2023
Planetary Processing is a technology company that specializes in providing a Software Development Kit (SDK) for the creation and operation of massively-multiplayer online games. Their platform simplifies the process of building and maintaining large-scale online games, allowing game studios to concentrate on game development rather than infrastructure. They cater to small and medium game studios, offering a software-as-a-service hosting platform that facilitates a toolkit for creating and running large-scale multiplayer games from scratch, using the game engine of choice. The platform handles network coding and server hosting, enabling game developers to focus on building their game.
PharmEnable
Seed Round in 2023
PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.
Zetta Genomics
Seed Round in 2023
Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.
Seprify
Seed Round in 2023
Seprify is a manufacturer specializing in cellulose-based white pigments designed to replace titanium dioxide in various applications. The company's innovative pigments are derived from renewable materials that are cost-effective, biocompatible, and easily processed. By offering sustainable solutions, Seprify enables businesses across multiple industries, including paints, inks, cosmetics, pharmaceuticals, and food, to create safer and more environmentally friendly products. With a vision for a circular economy, Seprify aims to cater to the growing demand for sustainable materials in the marketplace.
52 North
Seed Round in 2023
52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.
Kalium Health
Venture Round in 2022
Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.
Carbon Re
Seed Round in 2022
Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company’s Delta Zero platform employs deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By integrating continuous improvement methods with AI, Carbon Re aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing. This approach not only targets substantial reductions in carbon emissions but also aims to lower electricity and fuel costs for plants, thereby promoting efficient decarbonization in foundational industries.
Pretzel Therapeutics
Series A in 2022
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.
CardiaTec Biosciences
Pre Seed Round in 2022
CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.
Spirea
Venture Round in 2022
Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.
Colorifix
Series B in 2022
Colorifix Limited is a biotechnology company based in Norwich, United Kingdom, that specializes in textile dyeing services through innovative biological methods. Founded in 2015, the company has developed a pioneering process that uses synthetic biology to produce, deposit, and fix pigments derived from organisms such as microbes, plants, animals, and insects. This approach enables the conversion of agricultural by-products, like sugar molasses, into colorants suitable for dyeing textiles. Colorifix's technology offers a sustainable alternative to traditional dyeing processes, eliminating the need for harsh chemicals and significantly reducing water consumption and pollution. The company's focus on creating biodegradable, ethical, and non-toxic dyes positions it as a leader in the effort to minimize the textile industry's environmental impact.
Concr
Seed Round in 2022
Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.
52 North
Seed Round in 2022
52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.
Regulatory Genome
Seed Round in 2022
Regulatory Genome provides dynamic, granular, and interoperable machine-readable regulatory content powered by AI-based textual information extraction techniques. Regulatory Genome enables regulatory authorities to improve the accessibility and dissemination of regulatory information, while also enabling organizations to deepen their regulatory intelligence and digitize their compliance and risk management processes. RegGenome content is vendor-neutral, allowing it to be integrated into any application or system, allowing for the creation of an efficient ecosystem of providers and users.
Tenyks
Seed Round in 2022
Tenyks is a University of Cambridge spin-out focused on enhancing interactions between humanity and artificial intelligence to mitigate risks associated with advanced AI technologies. The company has developed a monitoring and validation platform tailored for machine learning engineers, particularly those working with computer vision data. This platform facilitates the rapid generation of production-ready models by enabling users to validate, test, and monitor model behavior effectively. It identifies common failure patterns and explains the reasons behind distribution shifts, thereby streamlining the troubleshooting process. By reducing the amount of labeled data needed to achieve high performance, Tenyks empowers AI developers to build more reliable machine learning operations efficiently. The foundation of Tenyks' technology stems from extensive research in Explainable AI, including two PhD and one Master's theses conducted at the University of Cambridge.
BKwai
Seed Round in 2022
BKwai is a company focused on enhancing the resilience of the built environment through advanced data insights and technology. It develops a software platform that significantly improves infrastructure asset management across the entire lifecycle of an asset. By harnessing data from on-site sensors and satellite imagery, BKwai employs artificial intelligence and structural engineering expertise to enable users to monitor the structural health of infrastructure effectively. This approach allows for smarter, faster, and safer management of construction and asset maintenance, addressing the untapped potential of data in the industry.
Semarion
Seed Round in 2022
Semarion is a company that emerged from the Cavendish Laboratory at the University of Cambridge, focusing on innovations at the intersection of physical and life sciences. It specializes in the development of a drug discovery platform utilizing advanced microcarrier technology to enhance the process of adherent cell screening. By integrating materials engineering with cell biology, Semarion offers unique, magnetically steerable microcarriers that support small cell colonies. This innovative approach facilitates more efficient and powerful assay workflows, positioning researchers to expedite the identification of drugs, particularly for GPCR-targeting oncology applications. Semarion aims to address unmet needs in drug screening and accelerate the advancement of new therapeutic options.
Signaloid
Pre Seed Round in 2022
Signaloid is a technology company that specializes in computing platforms and software solutions aimed at uncertainty-tracking in data inputs. Its offerings include a cloud platform and application programming interface that facilitate advanced computations and data storage. The company's technologies are applicable across various fields such as materials modeling, autonomous systems, computational finance, machine learning, and quantum computing. By leveraging its innovations, Signaloid enables clients to assess the impact of uncertainties on their decision-making processes, helping them to ensure compliance with regulations, optimize costs, and enhance safety outcomes.
Barocal
Seed Round in 2022
Barocal is a developer of innovative cooling technology focused on meeting low-carbon refrigeration needs. The company utilizes materials that experience significant thermal changes when pressure is applied or removed, leading to enhanced energy efficiency and a zero greenhouse warming impact. This technology is particularly beneficial for commercial food and drink refrigeration, allowing clients to effectively lower indirect greenhouse gas emissions. By prioritizing sustainability, Barocal aims to contribute to a more environmentally friendly approach to refrigeration.
Zetta Genomics
Seed Round in 2022
Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.
Carbon Re
Pre Seed Round in 2021
Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company’s Delta Zero platform employs deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By integrating continuous improvement methods with AI, Carbon Re aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing. This approach not only targets substantial reductions in carbon emissions but also aims to lower electricity and fuel costs for plants, thereby promoting efficient decarbonization in foundational industries.
Wave Photonics
Pre Seed Round in 2021
Wave Photonics is a company based in Cambridge, UK, focused on enhancing the design and integration of integrated photonics products. It develops a platform that utilizes computational techniques to optimize product designs and streamline the supply chain. This platform offers a software tool that predicts the performance and variability of components based on specific fabrication processes, along with an optimizer to create a library of foundry-specific components. By facilitating the development and mass production of integrated photonics technologies, Wave Photonics aims to improve efficiency and reduce redundancy for businesses in the sector.
Echion Technologies
Series A in 2021
Echion Technologies, founded in 2017 and based in Cambridge, United Kingdom, specializes in developing advanced anode materials for lithium-ion (Li-ion) batteries. Their proprietary XNO® material offers faster charging times, longer lifespans, and improved safety compared to traditional options. The company targets the heavy-duty electric vehicle market, aiming to enhance efficiency and sustainability within the transportation sector by providing optimized power anode materials for cost-effective battery production.
Porotech
Venture Round in 2021
Porotech is a spin-out from the University of Cambridge that specializes in the development of wide-bandgap gallium nitride (GaN) semiconductors. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on applying advanced material technologies to maximize the potential of GaN. This innovation aims to transform the electronics industry by enhancing the efficiency of light-emitting diodes and other electronic devices, thereby enabling a wide range of applications. Through its cutting-edge approaches, Porotech is positioned to contribute significantly to the advancement of energy-efficient semiconductor solutions.
Porotech
Seed Round in 2021
Porotech is a spin-out from the University of Cambridge that specializes in the development of wide-bandgap gallium nitride (GaN) semiconductors. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on applying advanced material technologies to maximize the potential of GaN. This innovation aims to transform the electronics industry by enhancing the efficiency of light-emitting diodes and other electronic devices, thereby enabling a wide range of applications. Through its cutting-edge approaches, Porotech is positioned to contribute significantly to the advancement of energy-efficient semiconductor solutions.
iKVA
Seed Round in 2021
iKVA is an AI knowledge management software company that develops a platform designed to discover and transform data into actionable business insights. Utilizing advanced machine learning, natural language processing, and semantic technology, iKVA indexes unstructured data from various sources, including document archives, emails, chat, and videos. This capability allows businesses to significantly reduce the time spent searching for information while minimizing risks by ensuring that accurate and relevant information is readily available. The company's focus on harnessing AI technology positions it as a key player in improving organizational efficiency and decision-making processes.
Abselion
Seed Round in 2021
Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of biological substances such as proteins, DNA, and small molecules. The company focuses on simplifying the analysis of these biomolecules for pharmaceutical research and manufacturing. Its diagnostic analyzers and kits facilitate the analysis of biomolecular interactions, including protein interaction analysis, enabling researchers to achieve sensitive and timely medical diagnoses. Through its innovative technology, Abselion enhances the efficiency of biomedical research and contributes to advancements in medical diagnostics.
Concr
Pre Seed Round in 2021
Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.
Nyobolt
Series A in 2021
Nyobolt is a technology developer focused on high-power battery solutions for the automotive industry. Founded in 2020 and based in Cambridge, United Kingdom, the company specializes in innovative battery technology that incorporates new materials and advanced cell designs. Nyobolt's batteries are designed to offer rapid charging capabilities and significant energy storage, catering to the demands of high-power automotive applications. By leveraging efficient software control and power electronics, Nyobolt aims to enhance the performance and reliability of electric vehicles, contributing to the advancement of sustainable transportation.
Cambridge GaN Devices
Series A in 2021
Cambridge GaN Devices specializes in the design, development, and commercialization of gallium nitride (GaN) power devices aimed at enhancing energy efficiency across various electronic applications. The company produces a range of GaN-based semiconductor products that significantly improve power conversion and minimize energy loss in systems used in sectors such as renewable energy, electric vehicles, and consumer electronics. These transistors are characterized by their speed, reduced power loss, smaller size compared to traditional silicon alternatives, and greater energy storage and conversion capabilities. By collaborating with industry partners, Cambridge GaN Devices promotes innovation and facilitates the adoption of its advanced technology within the power semiconductor market, contributing to the advancement of greener technologies.
NiftPad
Pre Seed Round in 2021
NiftPad is a company that empowers brands to create and sell unique digital assets through its innovative white-label shop platform. Founded in October 2021 as a spin-off from the University of Cambridge, NiftPad provides a no-code application that allows enterprises to easily launch non-fungible token projects. This platform enables businesses to build fully customizable online stores for issuing and selling digital assets, facilitating new avenues for revenue generation and enhancing community engagement. Backed by notable investors, NiftPad aims to simplify the process of entering the digital asset market for various brands.
Sano Genetics
Seed Round in 2021
Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, founded in 2017. It operates a user-centric genetic data-sharing platform that empowers individuals to contribute their genetic and health information for research purposes. The platform facilitates a direct connection between users and researchers, enabling the analysis of consented data to advance scientific understanding and personalized medicine. Sano Genetics supports a wide range of studies, including those focused on common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to choose from various research programs, the company aims to enhance recruitment for clinical trials and provide researchers with access to dynamic health and genetic datasets, ultimately contributing to the development of new treatments and cures.
Riverlane
Series A in 2021
Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.
8Power
Series A in 2020
8Power Limited specializes in the manufacture of autonomous sensor systems tailored for various sectors, including automotive, transportation, civil engineering, industrial equipment, and utility infrastructure. The company has developed a wireless sensor technology that provides real-time condition monitoring data and analytics, allowing industrial clients to continuously monitor the performance of their assets. This technology is particularly effective for managing thousands of remote assets, such as pumps, motors, and gearboxes, facilitating machine condition monitoring at a lower cost. 8Power's solutions are designed for easy installation and application across industries such as water and waste treatment, manufacturing, and oil and gas, enhancing operational efficiency and asset management.
Sorex Sensors
Seed Round in 2020
Sorex Sensors Limited specializes in the design and manufacturing of film bulk acoustic resonator (FBAR) technology-based micro-electro-mechanical system (MEMS) mass sensors for various industrial and consumer applications. Established in 2017 and headquartered in the United Kingdom, the company fabricates its devices on silicon wafers, utilizing a thin film of piezoelectric material. This innovative technology enables the sensors to measure mass by detecting changes in resonant frequency when mass is applied to the surface. Sorex's products are characterized by their ability to measure mass down to the femtogram range, simultaneous mass and temperature measurements with high sensitivity, and low power consumption. The sensors are particularly effective for thin film metrology, particulate monitoring, and gas detection, making them suitable for applications that require precise detection of small masses in compact form factors. Additionally, the functionalization of the sensor surfaces allows for selective detection of specific targets, enhancing their utility in various environments.
Bond180
Seed Round in 2020
Bond180 Limited is a fintech company based in London, United Kingdom, specializing in technology solutions for the debt capital markets. Founded in 2019, the company develops a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates communication between investors and the sell-side, and an issue administration network (IAN) that provides digital asset issuance and administration services. The company's focus is on enabling institutional investors to efficiently source assets and identify value in primary markets.
Colorifix
Series A in 2020
Colorifix Limited is a biotechnology company based in Norwich, United Kingdom, that specializes in textile dyeing services through innovative biological methods. Founded in 2015, the company has developed a pioneering process that uses synthetic biology to produce, deposit, and fix pigments derived from organisms such as microbes, plants, animals, and insects. This approach enables the conversion of agricultural by-products, like sugar molasses, into colorants suitable for dyeing textiles. Colorifix's technology offers a sustainable alternative to traditional dyeing processes, eliminating the need for harsh chemicals and significantly reducing water consumption and pollution. The company's focus on creating biodegradable, ethical, and non-toxic dyes positions it as a leader in the effort to minimize the textile industry's environmental impact.
PharmEnable
Seed Round in 2020
PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.
Qkine
Series A in 2020
Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacture of high-purity, animal-free growth factors, cytokines, and complex proteins designed to support advancements in stem cell, organoid, and regenerative medicine. Utilizing proprietary protein production processes developed at the University of Cambridge, Qkine combines these methodologies with protein engineering techniques to produce unique products that address critical biological and scalability challenges in fast-evolving life science sectors. The company boasts an active research and development pipeline, continually expanding its product offerings, which include innovative solutions such as tag-free thermostable FGF-2 and the first animal-free TGF beta 1 for chemically defined stem cell media. Qkine is committed to quality and is certified under ISO 9001:2015, ensuring that its bioactive proteins meet the highest standards to support its customers' scientific endeavors.
Flusso
Series A in 2020
Flusso Ltd, established in 2016 and headquartered in Cambridge, United Kingdom, specializes in the development and manufacturing of sensor solutions tailored to various industries. The company produces mass flow and air velocity sensors, leveraging proprietary technology to meet specific application needs.
Xampla
Seed Round in 2020
Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, focused on developing and producing plant protein-based materials as sustainable alternatives to conventional plastics. Founded in 2018, Xampla specializes in creating biodegradable and biocompatible products, including microcapsules, beads, films, threads, and various other structures made entirely from pea protein. These materials are designed for diverse commercial applications, spanning sectors such as food, cosmetics, household products, animal feed, packaging, and medical uses. By eliminating synthetic ingredients and reducing reliance on polluting plastics, Xampla aims to provide environmentally friendly solutions that align with the growing demand for sustainable materials in the marketplace.
Porotech
Seed Round in 2020
Porotech is a spin-out from the University of Cambridge that specializes in the development of wide-bandgap gallium nitride (GaN) semiconductors. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on applying advanced material technologies to maximize the potential of GaN. This innovation aims to transform the electronics industry by enhancing the efficiency of light-emitting diodes and other electronic devices, thereby enabling a wide range of applications. Through its cutting-edge approaches, Porotech is positioned to contribute significantly to the advancement of energy-efficient semiconductor solutions.
Kalium Health
Seed Round in 2020
Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.
AudioTelligence
Series A in 2020
AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.
Tenyks
Pre Seed Round in 2020
Tenyks is a University of Cambridge spin-out focused on enhancing interactions between humanity and artificial intelligence to mitigate risks associated with advanced AI technologies. The company has developed a monitoring and validation platform tailored for machine learning engineers, particularly those working with computer vision data. This platform facilitates the rapid generation of production-ready models by enabling users to validate, test, and monitor model behavior effectively. It identifies common failure patterns and explains the reasons behind distribution shifts, thereby streamlining the troubleshooting process. By reducing the amount of labeled data needed to achieve high performance, Tenyks empowers AI developers to build more reliable machine learning operations efficiently. The foundation of Tenyks' technology stems from extensive research in Explainable AI, including two PhD and one Master's theses conducted at the University of Cambridge.
Cambridge Energy Partners
Seed Round in 2020
Cambridge Energy Partners is a manufacturer of mobile solar trackers for the global commercial and industrial sector. Their trackers look and perform like traditional solar when installed, but arrive at site in prefabricated units, ready for fast deployment and connection (4x faster than traditional installations). Their product is a truly scalable mobile solar tracker, and offers users 'big solar' quality, while also reducing stranded asset risk - enabling the owner to deploy the asset multiple times over its 25-year useful life.
Spirea
Pre Seed Round in 2019
Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.
Porotech
Seed Round in 2019
Porotech is a spin-out from the University of Cambridge that specializes in the development of wide-bandgap gallium nitride (GaN) semiconductors. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on applying advanced material technologies to maximize the potential of GaN. This innovation aims to transform the electronics industry by enhancing the efficiency of light-emitting diodes and other electronic devices, thereby enabling a wide range of applications. Through its cutting-edge approaches, Porotech is positioned to contribute significantly to the advancement of energy-efficient semiconductor solutions.
Nu Quantum
Pre Seed Round in 2019
Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.
Bond180
Pre Seed Round in 2019
Bond180 Limited is a fintech company based in London, United Kingdom, specializing in technology solutions for the debt capital markets. Founded in 2019, the company develops a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates communication between investors and the sell-side, and an issue administration network (IAN) that provides digital asset issuance and administration services. The company's focus is on enabling institutional investors to efficiently source assets and identify value in primary markets.
PredictImmune
Series B in 2019
PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.
Paragraf
Series A in 2019
Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.
Riverlane
Seed Round in 2019
Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.
Qkine
Seed Round in 2019
Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacture of high-purity, animal-free growth factors, cytokines, and complex proteins designed to support advancements in stem cell, organoid, and regenerative medicine. Utilizing proprietary protein production processes developed at the University of Cambridge, Qkine combines these methodologies with protein engineering techniques to produce unique products that address critical biological and scalability challenges in fast-evolving life science sectors. The company boasts an active research and development pipeline, continually expanding its product offerings, which include innovative solutions such as tag-free thermostable FGF-2 and the first animal-free TGF beta 1 for chemically defined stem cell media. Qkine is committed to quality and is certified under ISO 9001:2015, ensuring that its bioactive proteins meet the highest standards to support its customers' scientific endeavors.
PolyProx
Seed Round in 2019
PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.
Sano Genetics
Seed Round in 2019
Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, founded in 2017. It operates a user-centric genetic data-sharing platform that empowers individuals to contribute their genetic and health information for research purposes. The platform facilitates a direct connection between users and researchers, enabling the analysis of consented data to advance scientific understanding and personalized medicine. Sano Genetics supports a wide range of studies, including those focused on common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to choose from various research programs, the company aims to enhance recruitment for clinical trials and provide researchers with access to dynamic health and genetic datasets, ultimately contributing to the development of new treatments and cures.
Morphogen-IX
Series B in 2018
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative treatments for pulmonary arterial hypertension (PAH), a severe and life-limiting condition that affects lung blood vessels and can lead to heart failure. Founded in 2015, Morphogen-IX is pioneering the use of bone morphogenetic proteins, particularly BMP9 and BMP10, to enhance BMPR-II receptor signaling in endothelial cells, which is crucial for addressing the underlying mechanisms of PAH. Current therapies primarily alleviate symptoms rather than addressing the disease's root causes, leaving patients with limited options. The company employs a semi-virtual model, leveraging a network of experienced professionals in drug discovery to maximize capital efficiency while maintaining high-quality research and development.
Colorifix
Series A in 2018
Colorifix Limited is a biotechnology company based in Norwich, United Kingdom, that specializes in textile dyeing services through innovative biological methods. Founded in 2015, the company has developed a pioneering process that uses synthetic biology to produce, deposit, and fix pigments derived from organisms such as microbes, plants, animals, and insects. This approach enables the conversion of agricultural by-products, like sugar molasses, into colorants suitable for dyeing textiles. Colorifix's technology offers a sustainable alternative to traditional dyeing processes, eliminating the need for harsh chemicals and significantly reducing water consumption and pollution. The company's focus on creating biodegradable, ethical, and non-toxic dyes positions it as a leader in the effort to minimize the textile industry's environmental impact.
Healthera
Series A in 2018
Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.
Silicon Microgravity
Venture Round in 2018
Silicon Microgravity Limited is a technology company based in Cambridge, United Kingdom, that specializes in developing advanced sensor devices for the oil and gas sector. Established in 2014 as a spin-out from Cambridge University, the company has created innovative microelectromechanical system sensors that enable high-sensitivity gravity data recording and seismic data capture at ultra-low frequencies. This technology, initially developed in collaboration with BP plc and funded by Innovate UK, represents a significant advancement in oil and gas reservoir management. By transforming how density measurements are taken deep within reservoirs, Silicon Microgravity aims to enhance reservoir surveillance and improve operational efficiencies, allowing clients to achieve cost savings while adhering to social, safety, and environmental standards. The company's technology also has applications in navigation, guidance, and the stabilization of intelligent systems across various sectors, including commercial, industrial, and military uses.
Sorex Sensors
Seed Round in 2018
Sorex Sensors Limited specializes in the design and manufacturing of film bulk acoustic resonator (FBAR) technology-based micro-electro-mechanical system (MEMS) mass sensors for various industrial and consumer applications. Established in 2017 and headquartered in the United Kingdom, the company fabricates its devices on silicon wafers, utilizing a thin film of piezoelectric material. This innovative technology enables the sensors to measure mass by detecting changes in resonant frequency when mass is applied to the surface. Sorex's products are characterized by their ability to measure mass down to the femtogram range, simultaneous mass and temperature measurements with high sensitivity, and low power consumption. The sensors are particularly effective for thin film metrology, particulate monitoring, and gas detection, making them suitable for applications that require precise detection of small masses in compact form factors. Additionally, the functionalization of the sensor surfaces allows for selective detection of specific targets, enhancing their utility in various environments.
Cambridge Touch Technologies
Series A in 2018
Cambridge Touch Technologies, Ltd., established in 2011 and based in Cambridge, UK, specializes in developing advanced 3D touch technology for various applications. The company's core product, UltraTouch, combines a proprietary AI engine with an innovative Piezoelectric Force Film to create a simplified, yet powerful touch and force sensor architecture. This technology offers superior functionality, lower costs, and scalability to diverse device sizes and shapes, including curved and foldable ones, catering to smartphones, tablets, automotive, and industrial sectors.
PhoreMost
Series A in 2018
PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.
Qkine
Seed Round in 2018
Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacture of high-purity, animal-free growth factors, cytokines, and complex proteins designed to support advancements in stem cell, organoid, and regenerative medicine. Utilizing proprietary protein production processes developed at the University of Cambridge, Qkine combines these methodologies with protein engineering techniques to produce unique products that address critical biological and scalability challenges in fast-evolving life science sectors. The company boasts an active research and development pipeline, continually expanding its product offerings, which include innovative solutions such as tag-free thermostable FGF-2 and the first animal-free TGF beta 1 for chemically defined stem cell media. Qkine is committed to quality and is certified under ISO 9001:2015, ensuring that its bioactive proteins meet the highest standards to support its customers' scientific endeavors.
Paragraf
Seed Round in 2018
Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.
Cytora
Series A in 2017
Cytora is a London-based company that offers a configurable platform designed to enhance the efficiency and accuracy of risk processing for commercial insurers. Founded in 2014, Cytora's platform digitizes incoming risks and enriches them with various data sources. It evaluates these risks using multiple criteria, including appetite and priority rules, and subsequently routes them for automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing it to compute ranks, scores, and prices for properties and organizations. This capability enables insurers to better target profitable risks, improve risk selection, and optimize pricing strategies.
PredictImmune
Series A in 2017
PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.
Z Factor
Series A in 2017
Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.
Focal Point Positioning
Series B in 2017
Focal Point Positioning Ltd. is a technology company based in Cambridge, United Kingdom, that specializes in advanced positioning, navigation, and timing solutions. Founded in 2015, it leverages smartphone-based sensor fusion, machine learning, and signal processing to offer satellite positioning capabilities in previously unreachable areas. The company has developed two core products, S-GNSS and D-Tail, which enhance the sensitivity and accuracy of GPS receivers and utilize existing smartphone sensors for precise three-dimensional tracking. Focal Point serves a diverse range of sectors, including defense, security, aerospace, autonomy, telecommunications, retail, logistics, and emergency services, addressing challenges in GNSS and GPS-denied environments. The company is led by Dr. Ramsey Faragher, a recognized expert in the field, who has a distinguished background that includes significant contributions to multi-sensor positioning systems and advanced navigation technologies for various applications, including unmanned vehicles and space exploration.
Cytora
Series A in 2017
Cytora is a London-based company that offers a configurable platform designed to enhance the efficiency and accuracy of risk processing for commercial insurers. Founded in 2014, Cytora's platform digitizes incoming risks and enriches them with various data sources. It evaluates these risks using multiple criteria, including appetite and priority rules, and subsequently routes them for automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing it to compute ranks, scores, and prices for properties and organizations. This capability enables insurers to better target profitable risks, improve risk selection, and optimize pricing strategies.
Polypharmakos
Series A in 2017
Polypharmakos Limited is a biotechnology company founded in 2016 and located in Witney, United Kingdom. The company focuses on discovering and developing novel antimicrobials derived from plants, fungi, and other natural sources to combat the growing global issue of antimicrobial resistance (AMR). By leveraging natural product sources, Polypharmakos aims to provide chemical-free alternatives for drug treatment, catering to the needs of the pharmaceutical, consumer health, and agri-tech sectors. The company's mission underscores its commitment to addressing the pressing health challenge posed by AMR, contributing to more sustainable and effective therapeutic solutions.
Cambridge Touch Technologies
Series A in 2016
Cambridge Touch Technologies, Ltd., established in 2011 and based in Cambridge, UK, specializes in developing advanced 3D touch technology for various applications. The company's core product, UltraTouch, combines a proprietary AI engine with an innovative Piezoelectric Force Film to create a simplified, yet powerful touch and force sensor architecture. This technology offers superior functionality, lower costs, and scalability to diverse device sizes and shapes, including curved and foldable ones, catering to smartphones, tablets, automotive, and industrial sectors.
Carrick Therapeutics
Series A in 2016
Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.
PervasID
Series A in 2016
PervasID Limited is a company based in Cambridge, United Kingdom, that specializes in the development of wide area passive RFID systems. Founded in 2011, PervasID focuses on providing location capabilities based on the EPC Class1 Gen2 standard. The company emerged from research conducted in the Engineering Department at the University of Cambridge and has since successfully deployed its technology in various field trials. PervasID's innovative RFID tracking system is designed to serve multiple industries, including retail, healthcare, supply chain and logistics, and aviation. Utilizing patented technology, the system employs fixed ultra-high frequency RFID to detect passive tags over long ranges with high accuracy, enabling organizations to enhance visibility into goods, assets, and personnel, thereby streamlining operational processes.
Fluidic Analytics
Series B in 2016
Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.
Cambridge Innovation Capital
Venture Round in 2016
Cambridge Innovation Capital, established in 2013, is a venture capital firm based in Cambridge, UK. It specializes in early-stage investments, focusing on life sciences and technology companies with affiliations to the University of Cambridge or the Cambridge Cluster. The firm invests in a wide range of sectors, including healthcare, therapeutics, medtech, digital health, genomics, and emerging technologies such as AI, IoT, and quantum technologies. Cambridge Innovation Capital typically invests up to £19 million per company, providing long-term equity finance to support the growth and commercial development of innovative businesses. As a preferred investor for the University of Cambridge, the firm has access to a robust pipeline of investment opportunities within the ecosystem. Since its inception, Cambridge Innovation Capital has raised £275 million to fund disruptive, deep-tech businesses.
Healthera
Seed Round in 2016
Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.
8Power
Seed Round in 2016
8Power Limited specializes in the manufacture of autonomous sensor systems tailored for various sectors, including automotive, transportation, civil engineering, industrial equipment, and utility infrastructure. The company has developed a wireless sensor technology that provides real-time condition monitoring data and analytics, allowing industrial clients to continuously monitor the performance of their assets. This technology is particularly effective for managing thousands of remote assets, such as pumps, motors, and gearboxes, facilitating machine condition monitoring at a lower cost. 8Power's solutions are designed for easy installation and application across industries such as water and waste treatment, manufacturing, and oil and gas, enhancing operational efficiency and asset management.
Psyomics
Series A in 2016
Psyomics specializes in the development of proteomic diagnostics aimed at improving early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers web-based assessment triage designed to facilitate diagnostic and pathway prediction for mental health conditions. By integrating digital profiling with cutting-edge biological research, Psyomics enhances diagnostic accuracy and supports primary care practitioners in effectively managing their patients' mental health needs. This innovative approach digitally replicates a psychiatric assessment at the initial point of contact, thereby enabling patients to achieve better recovery outcomes from mental health disorders.
DefiniGEN
Series B in 2016
DefiniGEN Limited is a biotechnology company based in Cambridge, United Kingdom, specializing in the production of human cell products for the life science and drug discovery sectors. Founded in 2012, the company utilizes its proprietary OptiDIFF stem cell production platform to create high-functionality cell types, including human hepatocytes and pancreatic cells, which are essential for predictive toxicology and drug discovery. DefiniGEN's offerings encompass a range of disease models, such as those for diabetes, hepatitis, and hypercholesterolemia, facilitating research and development in these areas. The company also provides custom services, including gene-editing custom cell line development and contract services for diabetes compound profiling. By leveraging advanced technologies and expertise in induced pluripotent stem cell production, DefiniGEN aims to enhance the efficacy and safety of new treatments, ultimately benefiting pharmaceutical clients in their research efforts.
ROADMap Systems
Series A in 2016
ROADMap Systems Limited is a technology company based in Cambridge, United Kingdom, specializing in wavelength selective switch (WSS) technology for fiber optic communication networks. Founded in 2013, the company addresses the growing demands of network operators by providing solutions that enable reconfigurable optical add/drop multiplexers (ROADMs). These advanced switches are designed to handle the increasing capacity required for high-speed internet data, specifically accommodating next-generation data rates of 400 Gbps. ROADMap Systems leverages four patents licensed from the Cambridge Centre for Advanced Photonics and Electronics to offer telecom and datacom applications that tackle challenges related to data rates, fiber management, power requirements, and network costs. By focusing on highly flexible optical switching capabilities, the company aims to meet the evolving needs of the telecommunications industry.
Cambridge Epigenetix
Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Morphogen-IX
Series A in 2016
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative treatments for pulmonary arterial hypertension (PAH), a severe and life-limiting condition that affects lung blood vessels and can lead to heart failure. Founded in 2015, Morphogen-IX is pioneering the use of bone morphogenetic proteins, particularly BMP9 and BMP10, to enhance BMPR-II receptor signaling in endothelial cells, which is crucial for addressing the underlying mechanisms of PAH. Current therapies primarily alleviate symptoms rather than addressing the disease's root causes, leaving patients with limited options. The company employs a semi-virtual model, leveraging a network of experienced professionals in drug discovery to maximize capital efficiency while maintaining high-quality research and development.
Silicon Microgravity
Seed Round in 2016
Silicon Microgravity Limited is a technology company based in Cambridge, United Kingdom, that specializes in developing advanced sensor devices for the oil and gas sector. Established in 2014 as a spin-out from Cambridge University, the company has created innovative microelectromechanical system sensors that enable high-sensitivity gravity data recording and seismic data capture at ultra-low frequencies. This technology, initially developed in collaboration with BP plc and funded by Innovate UK, represents a significant advancement in oil and gas reservoir management. By transforming how density measurements are taken deep within reservoirs, Silicon Microgravity aims to enhance reservoir surveillance and improve operational efficiencies, allowing clients to achieve cost savings while adhering to social, safety, and environmental standards. The company's technology also has applications in navigation, guidance, and the stabilization of intelligent systems across various sectors, including commercial, industrial, and military uses.
Cytora
Seed Round in 2015
Cytora is a London-based company that offers a configurable platform designed to enhance the efficiency and accuracy of risk processing for commercial insurers. Founded in 2014, Cytora's platform digitizes incoming risks and enriches them with various data sources. It evaluates these risks using multiple criteria, including appetite and priority rules, and subsequently routes them for automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing it to compute ranks, scores, and prices for properties and organizations. This capability enables insurers to better target profitable risks, improve risk selection, and optimize pricing strategies.
Quethera
Seed Round in 2015
Quethera Limited is a biotechnology company based in Canterbury, United Kingdom, focused on developing gene therapy treatments for glaucoma and other ophthalmic diseases. Established in 2013, the company aims to address progressive visual loss associated with these conditions, particularly in patients experiencing accelerated deterioration of their visual fields. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that assess the efficacy and safety of its innovative therapies. With a strong foundation in gene therapeutic design and development, Quethera is advancing its pipeline from preclinical testing into clinical development, striving to provide effective treatment solutions for common blinding eye diseases. As of 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.
Focal Point Positioning
Seed Round in 2015
Focal Point Positioning Ltd. is a technology company based in Cambridge, United Kingdom, that specializes in advanced positioning, navigation, and timing solutions. Founded in 2015, it leverages smartphone-based sensor fusion, machine learning, and signal processing to offer satellite positioning capabilities in previously unreachable areas. The company has developed two core products, S-GNSS and D-Tail, which enhance the sensitivity and accuracy of GPS receivers and utilize existing smartphone sensors for precise three-dimensional tracking. Focal Point serves a diverse range of sectors, including defense, security, aerospace, autonomy, telecommunications, retail, logistics, and emergency services, addressing challenges in GNSS and GPS-denied environments. The company is led by Dr. Ramsey Faragher, a recognized expert in the field, who has a distinguished background that includes significant contributions to multi-sensor positioning systems and advanced navigation technologies for various applications, including unmanned vehicles and space exploration.
Reduse
Series A in 2015
Reduse Limited is a company based in Cambridge, United Kingdom, that specializes in providing print removal services from paper using laser technology. Founded in 2015 by David Leal-Ayala, Hidde-Jan Lemstra, and Stuart Evans, Reduse aims to offer innovative solutions for the efficient recycling and repurposing of printed materials. The company focuses on sustainability by enabling the reuse of paper, thereby contributing to environmental conservation efforts.
Fluidic Analytics
Series A in 2014
Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.
Cambridge Epigenetix
Series A in 2014
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.